imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
imbruvica 140 mg kapseln
janssen-cilag ag - ibrutinibum - kapseln - ibrutinibum 140 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172, propylenglycolum, pro capsula corresp. natrium 2.73 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika
imbruvica 140 mg filmtabletten
janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 140 mg, lactosum monohydricum 28 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp. natrium 1.14 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika
imbruvica 280 mg filmtabletten
janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 280 mg, lactosum monohydricum 56 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp., natrium 2.28 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika
imbruvica 420 mg filmtabletten
janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 420 mg, lactosum monohydricum 84 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp. natrium 3.42 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika
imbruvica 560 mg filmtabletten
janssen-cilag ag - ibrutinibum - filmtabletten - ibrutinibum 560 mg, lactosum monohydricum 112 mg, carmellosum natricum conexum, natrii laurilsulfas, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum, talcum, e 171, e 172, pro compresso obducto corresp. natrium 4.56 mg. - mantelzelllymphom, chronische lymphatische leukämie, morbus waldenström - synthetika
fluconazol noridem 2 mg/ml infusionslösung
noridem enterprises ltd - fluconazol - fluconazol
diltiazem ethypharm 90 mg hartkapseln, retardiert
ethypharm (3370996) - diltiazemhydrochlorid - retardkapsel - teil 1 - retardkapsel; diltiazemhydrochlorid (20800) 90 milligramm
diltiazem ethypharm 180 mg hartkapseln, retardiert
ethypharm (3370996) - diltiazemhydrochlorid - hartkapsel, retardiert - teil 1 - hartkapsel, retardiert; diltiazemhydrochlorid (20800) 180 milligramm
diltiazem ethypharm 120 mg hartkapseln, retardiert
ethypharm (3370996) - diltiazemhydrochlorid - hartkapsel, retardiert - teil 1 - hartkapsel, retardiert; diltiazemhydrochlorid (20800) 120 milligramm